The Superior ETT for Intubated Patients

• Evacuates secretion through a patented, multiport vacuum appendage
• Appendage provides unobstructed suctioning away from the trachea wall
• Accommodates a wide range of patient positioning
• Excellent for patients who will be intubated for extended periods
• Reduces the risk of post-operative and ventilator-associated complications
• Radiopaque appendage enables fluoroscopic visualization to facilitate proper user placement.

The NeVap Aspire Subglottic Suction Endotracheal Tube (ASSET) evacuates secretions through a patented, multiport vacuum appendage. This appendage provides unobstructed suctioning away from the trachea wall to accommodate a wide range of patient positioning. In addition, the appendage is radiopacity enables fluoroscopic visualization to facilitate proper user placement.

Advantages

• 24 Suction fenestrations oriented so that vacuum is applied parallel to airway tissues.
• Vacuum>100mm Hg can be applied continuous.
• Higher pressures and continuous operation means improved removal of viscous fluids and reduced pooling and aspiration.
• Designed to reduce respiratory care needs.
• Superior Radiopaque confirmation of position and quieter operation.

Easy adoption

• Compliant with existing VAE/VAP prevention protocols.
• No new training required.
• No new capital equipment.

Features of NeVap ASSET

1. Improved fluid recovery rates (Suction-T enables continuous high vacuum operation)
2. Designed to reduce respiratory care needs (Less blockage due to airway tissue occlusion, from viscous fluids due to low, intermittent vacuum and less patient trauma due to airway tissue herniation)
3. Compliant with current VAP prevention protocols
4. No additional user training
5. Compatible with current equipment and protocols
6. Thermoplastic material construction allows for airway conformity at body temperature.

https://videos.files.wordpress.com/bNYRNYRF/nevap-lq-video-preso_dvd.mp4

Different sizes available:

Standard pack: Carton with 10 pieces.

CE-certified

FDA

 Externer Link: Artikel über VAP: https://www.jci.org/articles/view/170682

Mehr Info